Table 3 Pregnancy outcomes according to the group of risk
Clinically nonsignificant antibodies (n = 78) | Clinically significant antibodies (n = 259) | ||||
|---|---|---|---|---|---|
Paternal compatibility or negative fetal antigen (n = 65) | Not compatible, fetal unknown or positive fetal antigen (n = 194) | ||||
Titer< 1:16 (n = 38) | Titer> 1:16 or anti-Kell (n = 156) | ||||
Low risk | High risk | ||||
Miscarriage or TOP < 18 weeks | 2 (2.6%) | 2 (3.1%) | 0 | 6 (3.8%) | |
Normal MCA-PSV (n = 93) | Abnormal MCA-PSV (n = 57) | ||||
Termination of pregnancy ≥18 weeks | 0 | 0 | 0 | 1 (1.1%) | 6 (10.5%) |
Perinatal death | 0 | 0 | 0 | 3 (3.2%) | 3 (5.3%) |
Livebirth | 76 (97.4%) | 63 (96.9%) | 38(100%) | 89 (95.7%) | 48 (84.2%) |
Intrauterine transfusion | 0 | 1 (1.5%) | 0 | 0 | 44 (77.2%) |
Gestational age at birth | 39.0 (27.0–42.0) | 39.0 (33.0–41.0) | 38.0 (26–41) | 37.2 (26–42) | 34.0 (27–38) |